DDX52: A Potential Drug Target for Cancer and Neurodegenerative Diseases

Target Name: DDX52

NCBI ID: G11056

DDX52

DDX52: A Potential Drug Target for Cancer and Neurodegenerative Diseases

DDX52 (DDX52_HUMAN), a protein found in various human tissues, has been identified as a potential drug target or biomarker in various diseases, including cancer. Its unique structure and expression pattern across different tissues make it an attractive target for researchers to investigate.

The discovery of DDX52

DDX52, short for doublecortin-like repeat sequence 52, was first identified as a gene encoding a protein with a molecular weight of approximately 42 kDa. The protein is composed of 156 amino acid residues and has a predicted localization in the cell nucleus.

Following its identification, studies showed that DDX52 is highly expressed in various human tissues, including brain, heart, muscle, and liver. It is also expressed in various types of cancer, including lung, breast, and ovarian cancer.

The unique structure of DDX52

The structure of DDX52 is unique due to its repetitive sequence characteristics. It contains a doublecortin-like domain, which is a known protein-coding region that is characterized by a specific sequence of amino acids that is similar to the doublecortin protein. Additionally, DDX52 has a number of unique features that distinguish it from other proteins, including a potential N-end rule intron, a unique amino acid substitution at its C-terminus, and a disulfide bond formation in its C-terminus.

The expression pattern of DDX52

DDX52 is highly expressed in various human tissues and has been observed in various types of cancer. Its expression is also associated with the development and progression of certain diseases, including cancer.

In cancer, DDX52 has been observed to be overexpressed in various tissues and to contribute to the development and progression of cancer. For example, studies have shown that DDX52 is overexpressed in various breast cancer tissues and that it is associated with poor prognosis in patients with breast cancer.

The potential implications of DDX52 as a drug target

The potential implications of DDX52 as a drug target are significant. Its unique structure and expression pattern make it an attractive target for small molecule inhibitors, which can be used to treat various diseases, including cancer.

One approach to targeting DDX52 is to use small molecules to inhibit its activity. This can be done by binding to specific regions of the protein and preventing it from carrying out its function.

Another approach to targeting DDX52 is to use antibodies to target its expression. This can be done by using antibodies that recognize specific epitopes (regions) on the protein and then using them to block its expression.

The potential uses of DDX52 as a drug target

The potential uses of DDX52 as a drug target are numerous. Its unique structure and expression pattern make it an attractive target for small molecule inhibitors, which can be used to treat various diseases, including cancer.

One of the potential uses of DDX52 as a drug target is its role in cancer development. Cancer is a disease that is characterized by the uncontrolled growth and proliferation of cells. DDX52 has been shown to contribute to the development and progression of various types of cancer , including breast, lung, and ovarian cancer.

Another potential use of DDX52 as a drug target is its role in the treatment of neurodegenerative diseases. neurodegenerative diseases, such as Alzheimer's and Parkinson's disease, are characterized by the progressive loss of brain cells and can be treated with small molecules that target the abnormalities in the brain.

DDX52 may also be used as a potential drug target for other diseases, including cardiovascular disease, gastrointestinal disease, and skin disease.

Conclusion

In conclusion, DDX52 is a unique protein that has been identified as a potential drug target or biomarker in various diseases, including cancer. Its unique structure and expression pattern make it an attractive target for small molecule inhibitors, which can be used to treat various diseases . Further research is needed to fully understand the potential uses of DDX52 as a drug

Protein Name: DExD-box Helicase 52

Functions: Required for efficient ribosome biogenesis (By similarity). May control cell cycle progression by regulating translation of mRNAs that contain a terminal oligo pyrimidine (TOP) motif in their 5' UTRs, such as GTPBP4 (By similarity)

The "DDX52 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DDX52 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets